Amundi Acquires 240,126 Shares of DaVita Inc. (NYSE:DVA)

Amundi boosted its position in DaVita Inc. (NYSE:DVA) by 116.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 446,386 shares of the company’s stock after purchasing an additional 240,126 shares during the period. Amundi’s holdings in DaVita were worth $68,726,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in DaVita by 0.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 12,854 shares of the company’s stock valued at $1,922,000 after buying an additional 118 shares during the period. E Fund Management Co. Ltd. acquired a new position in DaVita in the fourth quarter valued at $328,000. Candriam S.C.A. acquired a new position in DaVita in the fourth quarter valued at $576,000. Inceptionr LLC acquired a new position in DaVita in the fourth quarter valued at $714,000. Finally, Raymond James Financial Inc. acquired a new position in DaVita in the fourth quarter valued at $3,864,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE DVA opened at $146.71 on Wednesday. The firm’s 50-day moving average price is $159.41 and its 200-day moving average price is $157.90. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The firm has a market capitalization of $11.74 billion, a P/E ratio of 13.66, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DVA shares. Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.